Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 485 clinical trials
Featured trial
BAY-94-8862/16244 - A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease

BAY-94-8862/16244 - A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease

  • 1058 views
  • 25 Mar, 2021
  • 1 location
Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial

The study is an double blind, randomized, multicenter phase 3 trial. The efficacy analyses are based on 570 Chinese patients with RAS wt mCRC treated with mFOLFOX-6 cetuximab. Study treatment continues until disease progression or unacceptable toxicity (ie, not for a fixed number of courses). The primary endpoint of the …

growth factor
platelet count
adenocarcinoma
modified folfox6
adenocarcinoma of colon
  • 7 views
  • 26 Feb, 2022
  • 1 location
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to osimertinib could possibly add to the

cancer
liver metastasis
lung metastases
gilbert's syndrome
metastasis
  • 36 views
  • 23 Mar, 2022
  • 10 locations
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

-small cell lung cancer (NSCLC) with documented advanced or metastatic epidermal growth factor receptor (EGFR) mutation (Phase 1b expansion cohorts A, B and C), to estimate the antitumor activity of

targeted therapy
epidermal growth factor
platinum-based chemotherapy
cancer treatment
osimertinib
  • 10 views
  • 12 May, 2022
  • 77 locations
Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (GEOMETRY-E)

treatment in patients with advanced or metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation, T790M negative, mesenchymal-to-epithelial transition factor (MET

egfr t790m
epidermal growth factor
cancer chemotherapy
lung carcinoma
tyrosine
  • 0 views
  • 30 Apr, 2022
  • 12 locations
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2)

advanced or metastatic epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution non-small cell lung cancer (NSCLC) after osimertinib failure.

epidermal growth factor
platinum-based chemotherapy
non-squamous non-small cell lung cancer
squamous non-small cell lung cancer
osimertinib
  • 7 views
  • 08 Apr, 2022
  • 103 locations
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON)

chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.

epidermal growth factor
cancer chemotherapy
lung carcinoma
carboplatin
pemetrexed
  • 33 views
  • 10 May, 2022
  • 224 locations
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA)

The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR

solid tumour
epidermal growth factor
lung carcinoma
cancer treatment
stage iv non-small cell lung cancer
  • 114 views
  • 16 May, 2022
  • 265 locations
  • 208 views
  • 05 May, 2022
  • 158 locations
  • 767 views
  • 25 Apr, 2022
  • 15 locations